Pegcetacoplan substantially reduced proteinuria in these potentially debilitating rare kidney diseases in a new phase 3 study ...
The results highlighted the strength of systemic pegcetacoplan treatment in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN ...
Pharmaceuticals and Sobi announced that results from the Phase 3 VALIANT study were presented as an oral presentation during the ...
Zacks.com on MSN1mon
Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EUApellis further reported that the CHMP opinion was issued despite broad support for pegcetacoplan from the European retina ...
The results highlighted the potential of systemic pegcetacoplan treatment in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN ...
Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favoured treatment with pegcetacoplan ...
Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favored treatment with pegcetacoplan ...
The results highlighted the potential of systemic pegcetacoplan treatment in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback